-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CibYKEMsglRLMISLqfj3G4ZFxFfc1aU16EqB9bDIAMSfOezgIkXlKvvgvcXavIu/
 w7XGi5fV9JaGrROBcv0X0w==

<SEC-DOCUMENT>0001299933-11-000095.txt : 20110106
<SEC-HEADER>0001299933-11-000095.hdr.sgml : 20110106
<ACCEPTANCE-DATETIME>20110106170618
ACCESSION NUMBER:		0001299933-11-000095
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110101
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110106
DATE AS OF CHANGE:		20110106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		11514880

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>htm_40336.htm
<DESCRIPTION>LIVE FILING
<TEXT>
<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> Cumberland Pharmaceuticals Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	January 1, 2011
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	Cumberland Pharmaceuticals Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	001-33637
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	62-1765329
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	2525 West End Avenue, Suite 950, Nashville, Tennessee
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	37203
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	(615) 255-0068
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
Election of Joey Jacobs to the Board of Directors <br>On January 6, 2011, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference, announcing that Joey Jacobs has been appointed to the Company&#x2019;s Board of Directors, effective January 1, 2011. Mr. Jacob&#x2019;s compensation for his services as a director will be consistent with that of the Company&#x2019;s other non-employee directors. The Company has summarized the compensation it provides to its non-employee directors in its most recent Proxy Statement filed with the Securities and Exchange Commission on March 22, 2010. Other than with respect to compensation, there are no arrangements or understandings between Mr. Jacobs and any other person pursuant to which he was elected as a director. Mr. Jacobs does not have a direct or indirect material interest in any party with respect to any transaction with the Company, as defined under Regulation S-K It
em 404(a).  Mr. Jacobs has not been appointed to any committee of the Board of Directors.
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><!-- Item START -->
<P ALIGN="LEFT">
<FONT SIZE="2">
<B>
	Item 9.01 Financial Statements and Exhibits.
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
(d) Exhibits <br>      <br>  <br> 99.1   Cumberland Pharmaceuticals Inc. Press Release dated January 6, 2011<br> <br>
</FONT>
</P>
<!-- Item END -->
<BR><BR><BR><BR><P ALIGN="LEFT" STYLE="FONT-SIZE: 10PT"></P><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	Cumberland Pharmaceuticals Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	January 6, 2011
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	David L. Lowrance
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: David L. Lowrance
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: CFO
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Cumberland Pharmaceuticals Inc. Press Release dated January 6, 2011
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> EX-99.1 </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">

<BODY style="font-family: 'Times New Roman',Times,serif">


<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt"><img src="e32394-1161437694ff68e92c_1.jpg">
</FONT>

<P align="center" style="font-size: 12pt"><B>CUMBERLAND PHARMACEUTICALS ANNOUNCES</B>



<P align="center" style="font-size: 12pt"><B>JOEY JACOBS HAS JOINED ITS BOARD OF DIRECTORS</B>



<P align="left" style="font-size: 12pt"><B>NASHVILLE, Tenn. &#151; January&nbsp;6, 2011 &#150; Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) </B>is pleased to
announce the addition of Joey Jacobs to its Board of Directors.


<P align="left" style="font-size: 12pt">A healthcare veteran with more than 30&nbsp;years of industry experience, Mr.&nbsp;Jacobs is the former
Chairman, President and Chief Executive Officer of Nashville-based Psychiatric Solutions, Inc.
(PSI), which he co-founded in 1997 and grew into a $2&nbsp;billion behavioral healthcare system before
the company&#146;s sale to Universal Health Services in 2010.


<P align="left" style="font-size: 12pt">Prior to founding PSI, Mr.&nbsp;Jacobs spent 21&nbsp;years at Hospital Corporation of America (HCA)&nbsp;where he
served in various capacities, including President of the company&#146;s Tennessee Division.


<P align="left" style="font-size: 12pt">In addition to serving as Chairman of the Nashville Healthcare Council, he is a director for the
Federation of American Hospitals, the National Association of Psychiatric Health Systems and the
Monroe Carell, Jr. Children&#146;s Hospital at Vanderbilt.


<P align="left" style="font-size: 12pt">&#147;We are honored to welcome Joey to our Board of Directors,&#148; said A.J. Kazimi, Chief Executive
Officer of Cumberland Pharmaceuticals. &#147;Throughout his career, he has maintained a strong focus on
quality and growth while creating significant value for stakeholders. His hospital industry
perspective, entrepreneurial insight and experience building a successful public healthcare company
will be of tremendous value to Cumberland.&#148;


<P align="left" style="font-size: 12pt">Mr.&nbsp;Jacobs&#146; appointment is effective January&nbsp;1, 2011. He will serve as a Class&nbsp;I Director and hold
office until Cumberland&#146;s 2011 annual shareholder meeting, at which time the company&#146;s Class&nbsp;I
Directors will be elected for a term expiring in 2014.


<P align="left" style="font-size: 12pt">SOURCE: Cumberland Pharmaceuticals Inc.


<P align="left" style="font-size: 12pt"><B>About Cumberland Pharmaceuticals</B>


<P align="left" style="margin-right:2%; font-size: 12pt">Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused
on the acquisition, development and commercialization of branded prescription products. The
Company&#146;s primary target markets include hospital acute care and gastroenterology. Cumberland&#146;s
product portfolio includes Acetadote<sup>&#174;</sup> for the treatment of acetaminophen poisoning,
Caldolor<sup>&#174;</sup>, the first injectable treatment for pain and fever approved in the United
States, and Kristalose<sup>&#174;</sup>, a prescription laxative. Cumberland is dedicated to
providing innovative products which improve quality of care for patients. For more information
on Cumberland Pharmaceuticals, please visit the Company&#146;s website at
<U>www.cumberlandpharma.com</U>.


<P align="left" style="font-size: 12pt"><U>Investor Contact:</U>
<BR>
Angela Novak
<BR>
Cumberland Pharmaceuticals
<BR>
615-255-0068
<BR>
<U>investors@cumberlandpharma.com</U>


<P align="left" style="font-size: 12pt"><U>Media Contact:</U>
<BR>
Rebecca Kirkham
<BR>
Lovell Communications
<BR>
615-297-7766
<BR>
<U>rebecca@lovell.com</U>


<P align="center" style="font-size: 12pt"># # #




<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->
</BODY>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>e32394-1161437694ff68e92c_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 e32394-1161437694ff68e92c_1.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`!:`8P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^^BBBB@`H
MIK,J*SLRJJJ69F(5551DLS'@*`,DDX`Y/%?,/Q%_:W^%/P_TN#5[4Z[\0+.Y
MA\-W]O<^`K.RU#2[K0?%$4]U9^)=,\3ZSJ.@^$/$&BVEE"EYJ(\,^(=:UB""
MZLO)T>YDNH4;6C0K8B2A1I3J2?2$6]]KO97V5VKO3<3E%;M+U9]/DX!->0^&
M/C'X<\6_&3XJ_!W1+K1-2U3X0^&OACJOB^XTSQ%9ZEJ.B^(?B5_PFNH6WA#Q
M%H%K`T_AS5+'PIX>\,>+[<:C>FZU;0O'FBW\>G6E@;.^U7^?7]LC_@M]\6?"
M6A^*/#_P+^$_ACP5JC76K:?H_C_QIK<OCF^30Y;"]M+/6K3P7;Z1X<T?0O%]
MM>7%GJEK!JVM?$#PQ:RV#6=_INOVMV^S#_X-K/B7X^^,<?\`P4'^)_Q1\6:O
MXW\?>-/CA\.=9\2^)]<G6:_U*]D\(Z_`@"1I%:V-A96L%OI^DZ1IUO9Z3HNE
M6MEI&D6-EIEE:6D/V,N"<RP?#V:Y_F4:6'IX6&#AA*$:T*U:K6Q./PU&52?L
M92IPI0HRJQY74E4E4J0?)!0;?CU<WIK,\ORVBG*6*J5_:S<6HPA1PU2I9<R4
MG)U.2]DERWM+O_4+1117Q)[(4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`5XM\>_C[\./V;_AWJ/Q(^)>JO::9;S1Z9HFC:>L%SXE\
M9^)[N&XFTKPAX2TR:XM4U+7]46UN9D6>ZLM*TG3+/4O$7B35-$\+Z-K>MZ;[
M23CD\`<DGM7\F?Q&UOX^?\%5?VOM?\2_!?P5?Z[\$/A7JVJ_##X>>.%N=7MO
MA=IGAO3/$&A0>)?'>H>)=8DC\/Q>)/',VIZ+XSO_``UX7TW_`(6#?_#S3O"-
ME)X:\4R>!AJ-?0\.Y+3S;$5JF+Q$,'EF`IPKYABJDXTU&,Y.-'#PG/W8UL1*
M,U!M.T*=648SE&,)<N)Q/L/9PA%U*U:3C3@M7I9SFU_+"+N_-Q6E[K]!/#O[
M1_Q"_:<\0:3JGCNWT_0_#UN;>33OAOH5]>W_`(4L;BT\1VWB+3-2U>>]ALF\
M9^)M)O--\/\`V'Q+JFE:;;6%WH,6L>%?#'@R\U;6X;SO?VH<GPU$3U_LN,G_
M`+\_IR:]+^!7_!/;6_!&@/%X]^*K6>LWWAJUMXX_ACI-DMUX/\52"Z&HZCI7
MBSQSIVMZ9XNT^W26U&CP:U\+]$B%U:2WFJZ?J$-U%IUC]>:Y^R_\(?%=WX4U
M#Q?I?B#Q1?\`A&R2SLWOO&/BG3-+UA_(C@N;SQ7X3\,ZKH/@KQ5<7AC$[0:[
MX;O=.T^=G?1;#2U=D/7BLPRO#YE1J8-REA,(Y1IPHTVKV<6^7VDJ:DIN*YJC
M<I-Q<GSWYI.$:KIOG7OSLVV]5=ZWZV6OZ+6Q_"Q^UT?WFH_6?_T*OUN_X-8^
M/A_^VZ3P#\6_AJ0>QQX6\1YQZXR/SK^C+6_V/_V3?$\8B\3?LP_L]^)$V[<>
M(/@S\.=:R#C.[^TO#ESG=M&<]<#/08_`#_@HKX,\(?LI_M*:/HG[+WA;PY^S
M?HVN_!3P5XCUK2/@)H>F?![3-8\0GQW\5]-.O:I8?#VU\.VFH:T=.LK/3SJM
MW#+?&QM;:T\_[/!%&OTV=<?X/,^&<5D%++\33J8EX.V)J5:7LX?5L30KN].*
M<GS*DXJTE:Z?2S\:.25(YM@LQ=>'+A7B).GRRO-UZ+I))W]WE;N]&G:UU>Z_
MJ)R`<$@$YP,\G')XZ\=Z6OXIM$_;E_:^^'NLOKGA[]HCXI7-XUK/:-!XN\2W
M7Q"T@PRN'8C0?'__``DVB)<AQNCOH]/2^A#2)#<QQS2H_P!W?`?_`(+G?$+0
M-1TKP[^T9\-=)\=:*T6EZ?/XW^'13PQXS@-M!>+J&L:IX7U*YF\)>*=2U68V
M#?9-'O?AKIFG;;R2&&X22WM(/RT^B/Z:Z*\8^"7[07PC_:'\*Q>+OA1XQL/$
ME@([9M1T\K+IWB'09;J2[A@MO$'AZ_6'5M(EGGT_4(K.2[MEM-46RN+O2+J_
ML!'=/[/0`445_(Y_P4*_X*,?\%1/B+_P5AO?^"9O_!/#QEX`^"FK^`?#MC,=
M=UW0O`GB:X^)^K:Q\&/#_P`=-7U/Q'J?Q*\">.-,\*:=X7\-:D=!\.:)X<T2
M"[OM3M]7U?7O$&KVVLZ'H_A'W<@X?Q?$6+Q&&PM?!86&#P.(S'&8O,*\L-A,
M+@\,Z<:M:M5C2K32YZM."Y:<O>FKVCS27DYQG&&R6AAZ^)I8FN\5C*.!P^'P
M=*-;$5\37C4E3ITX3JT8-M4Y-N52.BLKR:B_ZXZ,U_)+_P`*=_X.S?\`H['X
M"_\`A,_LQ_\`T,]>/?"__@H__P`%B?V(O^"F'[+_`.Q[_P`%%OB#\-OCSH/[
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M?[5W[47_``5+^'G[0'Q4E^(/@_\`9N^-/A?P9\&=(?P=\/?"_P#PB'AV_P#B
M)^T5H=W9-?>"O"7AO4O$,DVE^!?"ULU]XIO-;OQ_9AF2Y6>]OY;DP63XO'9=
MF^9T94%A\EI8.KBXU)SC6G''8NG@J*P\8TY0G)5JD74]I4I*,+RBY-<H8O,\
M/@L7EN"JQJNMFM7$4<.X1BX1EAL/+$U'6;G%QBZ<&HN$:C<K)I+4_H:S17X6
M_P#!P7^V)^T=^Q%^Q1X'^+O[+_Q';X8?$+5OVC/!/@74/$`\)>!/&8N?"FK^
M`/BEK.HZ4VD_$/POXLT./[1J7AS1KH7T.FQ:E";,0V]Y%;W%U#/[-_P1Z_X*
M&7/[>G[.%W;?$VPU#PE^U9^SUJUM\)?VH_`/B&TLM%\267Q!TQ+VR7QM+X9@
MM=)NO#NF>.[C1=;DDT&^\.^'V\+>--!\=^!K.UU#3_"%MKVK]<N&LS7#M/BB
M,*53+)8ZI@:CIU&Z^'J4XTW[6O2<(J.'G.K"E"K"I42JSA"HJ;J4^;!9Y@'G
M<\@<ZD,?'"0QD5.FE1JPFY^Y2JJ;<JT8PE4E3E"'[N,I0<U"?+^ME%4M1U&P
MTC3[W5=4O;33M,TVTN+_`%#4;^YAM+&QL;2)Y[J\O+N=XX+:UM8(Y)KB>:1(
MH8D>21U121_&9\&/^"[G[2'[8/\`P6G^%7P2^"?Q%L?#7[#&O?%'5?AUH7@V
MS^'OA1M1^*GA?PQX9\77J_$?Q!XG\:^$KGXE:'?>-]8LXM9T[1M%OO`\6@>$
M[;PUH&J>'SXFMO%FM^(C).&LSS^EFN(P,:4</DV`K9AC<1B)3A2C"E3J550@
MZ=*JYXFM3HUI4:;C&#]E-SJ4TDV9KGF`R>IEU'%RJ.MFF-HX+"TJ,(SJ.=:K
M3I>UFI5*:C0I3JTHU:G,Y1=2'+";;2_M`SCK17R[^V_\0_&'PB_8M_:[^+'P
M\U?_`(1_Q]\+_P!F#X^?$3P/KPL=-U3^Q/&'@KX4^+/$GAG5QIFLV>HZ/J']
MFZUIME>_8=5T^^TV[\C[/?6=S:R2PO\`R`_L&_M#_P#!R7_P44^$GB+XS?L]
M_MD_">+P=X5^(>J_##4U\??#7]G/PYJQ\2:+X9\(>*KLVUI:?LSZ['/I_P#9
M?C71A'=/>K-)<B[C>W584FGZ<CX4Q6>8''9E',\FRO!8"OA\/7K9OB\1A8NK
MB$W3C!T,%BXRNDE[SAJ]%+6V&:<0X?*\9@\`\#F>/Q6.HUJ]&EEV'HUY*GAW
M!57/VN)H6LIQ:MS7U6CMS?W045_)E=_!+_@[&M;2YN8OVP_V=[^6""6:*QL_
M"W[.@N[V2-"R6MLU[^RO96:SW#@11-=W=K:J[AKBY@A#RI]*?\&]/_!3+]IW
M]OKP;^TCX#_:GN?#7B?Q[^SAJWPRC@^)FD:'I?AC6_&EE\3Y_BD9[#Q5X>\+
MV>E>";/4?"=WX`%E8ZEX3T70['5-*OK6*]TI]5L+S7=;Z<=P7BL)E./SC#9U
MP[G&%RQX7Z_#*,PKXG$8:&-K1P^'JSHU\%A?W4JTE"\92:NWRVA-K'"\3X>O
MF&#RVOEF<Y;B,>L0\)+,<'2HT:TL+15>O"%2EB:]YQI7E:R5EO?0_HYHK^9S
M_@X]_P""@'[77[!WA;]DK4OV4/BV?A3??$OQ%\8[+QM./`OPT\<#6[3PKI?P
M[FT*!H?B1X-\86VGBRF\0:I+YFE0V,]P9U6YEFCBB1/!U^#W_!V8PR/VLO@(
M1[>&OV8C^H_9GQ^1(_'(#P/!>(QF4X'.:^>\-Y3A,QGBZ>$AFV88K"XBK+!5
ME1Q'+"GE^(@U"3@VXU)6C4@Y)-V%B>**%#,L9E='*LZS#$8".%EBI9?A,/6I
M4EC*?M:%YU,;1G[\5):TX^]"27,E<_K;HK^20_![_@[,4%C^UA\!B%&2!X8_
M9C)(')``_9GR21Q@<GI7]&?[;WQ$\9_"#]B;]K[XL_#W6#X>^(7PO_9<^/WQ
M#\#Z^;#2]6;0O&7@GX3>*_$GAG6#I>N66IZ)JC:7K>F65Z;#6-.U'2KTP?9M
M0LKRSDF@D\[,.'G@<1E^&HYUD.;5,PK.A!Y3C<1BH8:?/0IQ>,=3!8>5*%25
M=>S<(UG)4ZONIQ7-V8/.?K5+%UZN5YME\,'2]M/^T,-0HNM#DJ3E]7]GBJRG
M*"IVDINFDYT[-J3Y?JBC..3P*_AC_8/_`&@_^#DO_@HE\(O$?QI_9[_;+^$L
M7@WPK\1]7^%NIIX^^&W[./AS6/\`A)M%\,^$/%=V;>QL?V:-<BETXZ7XUT;R
MKHW<;O<_:XC;HL*R2_0'QUTG_@ZD^`'P:^)OQO\`%G[6_P`$=<\)?"7P3XC^
M(GB^Q\)>#OV9;OQ!%X2\(:7<Z[XFU+3[37OV:?#NGWLFCZ'8WVJR6`U2._O8
M;.2UTJVO]3EM;&X^@K^'E?#8V678GBO@NACH5EAYX:KF^-A5A6<HQC3E&64K
MEF^9-*36C5[;'D4>,J.(PL,;0R#B6MA*E'V\*]/`865.=%+F=16Q\I<ME)Z1
MD]-%*ZO_`&.49'K7XS_\$+?V^?BK_P`%#?V)C\5?C;8:2GQ0^&WQ/USX&^+O
M$VB0Q:=8?$6^\*^#_`WBZU\?OX>M+>WTWPQJVM:7X\T^R\1Z1HX&A2^(M*U3
M6/#]EX=T+5M,\(^'OA;_`(*=?\%#?VP_V>O^"S7_``3S_91^#_Q@;PA\`?CG
M<_LKK\4O`(\!?#'7AXG7XC_M4^.?AKXS!\4>)O!>M>,]&_MGP5H^GZ/CP_XB
MTH:<8/[2TH6.KO)?OXE'A+-JN?8_AQO"TLQRZ&.J8AU*TUAW'`4I5JKI5(4:
MDI^T@DZ%Z<.;GCSNFN:WIU>(LOI9/A,\M7J8+&O!JBJ=.+K7QU6%*ES0G4A&
M/+.:]I[^B3<>?1/^H&B@<?Y_.BOF$[I/OJ>\%%%?SL_\%M?^"B'[4WP6^(O[
M,/[#/_!.^74I/VV/VA==A\8;],\)^%/%D^B?"R*37M`TJ'[!\1_"^N?#Z*U\
M8>(M(\4:GK'B[5+N.U^&_A3X5>*]:\5)HFBZQIGB2V]7)<HQ6>YA1R[".C3J
M58U:E3$8JHZ.$PM"A3E6KXG%5U"?L:%&E"4YS<9:*T5*3C%^?F>98?*L'4QF
M)564(2ITX4J%/VN(KUJU2-*CA\/2YH^TKUJDXQIPYHW=VVHQDU_1-17XR?\`
M!#S_`(*/WW_!1']D*UUGXEZ]I.H?M*_!?5E^'GQXMK.PT3P_/K=[(+N]\#_$
MZW\-:3JU\+#2OB!X9A\F_O$TKPMHEU\2O"WQ,L/"?AO3/#&CZ7`O[-UEFF68
MO)\QQ>5XZ"ABL%7E0JJ#;A*UG"I2E)1<Z5:G*%6C.T?:4IPG9*1I@,=A\SP6
M&Q^$ESX?%4HU:3=E))Z.$TG+DJ4Y)TZL+MTZD90E[T6A,CU'YTM?Q>_\%&?^
M"X?[9/[!'_!7?XF_#.PUFT^)O[)?PYC^$T^M_`6^\)^!M,F.B>,?A1X`UWQ#
MJ.C?$VP\)1_$#3]?C\2>(+S4M#?7?$^J^'!?WMOHMWI,NE/:6<']6W[*G[5?
MP3_;.^"7A'X^_`/Q?;>+?`?BRW9>0EKKGAO7;1(1K7A+Q;HWG3W&@^*-!N9E
MMM2TRX>1&5[;4-.N=0T?4--U.]]3-N%,XR;+<JS?%4J<\OSC"T,5AL3AISJT
MZ7UBFJM/#8ERIT_8XGV;4^3WH25_9U*G)4Y>#+N(,NS/&YAE]"I*&,RW$5:%
M>A6C&$ZBI25.6(P]IR]KA_:>YS>[.#Y55IT^>FY_1F<=:*_$'_@OW^UY^T1^
MQ3^P[HOQ@_9D^(9^&7Q&N_CQX#\%W'B(>$_`WC/S/#6M>&_'6HZEIO\`9'Q!
M\,^+-!7[3>:-ILOVQ-+74(/LYCM[J&*>X27]&?V&_B'XQ^+O[%?[(?Q8^(FL
MMXC^('Q/_9C^`WQ#\<^(&L=,TMM<\8>-?A;X6\2>)M8.F:)9:;HVF_VEK6I7
MUZ-/TC3M/TJR$_V73K&TLXH;>/AJY-BZ.2X3/9SH/!XW'8K+Z4(SJ/$JMA:5
M&M4E.FZ2IJFXUHJ,E6E)R3O3BM3IIYIAZF:XC*(JK]:PV#H8VI)PBJ+HXBI4
MI4U":J.3FI4I<T73BK-6D]4?4N:*_DW_`."X'[?7_!1;X"_\%"_V4?V3OV(?
MCE:?#-?VA_A[\,M+T[0-3^'OP;\3Z9J'Q0^)'QK\:?#/1]0U#Q!\1?AQXTU;
M2-/E%KX?MKQ;2Z73[2"VFO4L&N)+AI\F7X._\'9IAE(_:O\`@3(1%(RQQ>&_
MV8HI92J,1%$[?LUQ(DLF-D;230H'*EI8Q\P^AH<#8B>79;F>+X@X6RNCFM"6
M)PE',\SQ6'Q4J,*TJ$ISI0RVM&*52$E>-2<-KRO='DUN*:%/&X_`4,HSW'U,
MMJTZ.*JX#!8>M1C4JT*>(A&,IXRE*3]G5BW[B=T[*S1_6]1G'6OXP+S_`(*L
M?\%O_P#@E_K7PUOO^"I?[/>@?%7]GWQA\0K[1-7^+.@:5\-+7QO<6ITYO(T+
MPKXO^!OB:R^$&@:W!#!<^,/#/@_XH?#_`$3Q1\1=,T+Q1I%MK^@P6^H>)_"?
M]-_Q&_:MTK5_V3_`G[1?[/&M>#_%^E_&_6OV=/"WPI\7>)H]3@\):>/VFOBY
M\-_@_P"'?'?B'PW+?^$_$>JQ>`[CXE6_BW5_A9-K7@/Q;XIN_#UQ\-SXC\">
M(M5&M:/YV:\)YGE,L!*57+\PP695GA\%FF58V&-RZM6C*$:E'ZQ",94ZM/G3
ME3JTX2:4^13=.HH=67<18#,5BH0IXS"8O!0]KBLOS##3PF-I4VFXU/95/=J4
MYV:C4ISG&]KM*4'+[0R#T-%?B-_P3W_X*&?&C]H[4?A1KGQ#\-:"/`7QUN;7
MPQI^F:/+XMUKQ[\,/BSK_P"S\O[6MEI_B:X\1?"3X");_"6#X-W6FZ7'J%M\
M/O%>BZ9KGB_X%ZAX/_:&_:+L/C?K<WP8_;FO)S/+,7E&*>$QBI^U45.]*?/!
MQ;E%VE:+O"<)PE>,7S1=ERN+?J8/&4<=1]M1YN3F4;37+)-PA45UYPJ1DO6U
M[II>??%GP=K'Q#^%WQ'\`^'?&&I?#W7_`!KX$\6^%-#\?:-:I>ZQX(UCQ!H-
M]I6F>+M)M)+BT2YU/PY?7<&LV$#75L);JRB7[1#_`*Q8?A'\(OAQ\"/ASX3^
M$WPE\)Z9X*^'_@C28M&\.>'M*20PVEHDT]U/<7=Y<R3ZAJ^L:IJ%U>ZOKWB#
M6+N_UWQ%KNH:EKNO:CJ.L:C?7UQU/BJSUS4?#/B+3_#.KQ:!XCOM$U6ST#79
M[-=0AT;6;FQGATS59;!PR7L>GWKPW;VKJ4N%B,3`JQ%>1?"CX_>$?B(UOX>O
M[M?#WC^.VLS<^&M8M+O0+G5IIK/4+R:7PY8:P4O[F2WATC5+G5O#TF_Q)X6B
MM&/B"RM[.?3=2U/D]M55%X=3DJ,JBK2IIVC.JH\D9S2^.4(N4:;E?V:G4Y+>
MTGS=')'G]I9<_+R<W50OS.*?12DDY)?$XQO?EC;WNBBBLB@K\,O^"E_['G[1
M_P`?_C[X<\;?"'X;MXP\,V7P<\+^$[K4E\7^`M`,.OZ;XV^)&L7EB;/Q3XIT
M._<0Z=K^DW'VJ*U>SD-UY,5P\\%S'#^YM%`'\>VM?\$O/VZW2>6/X%32K%&[
ME8OB-\))9'&"V(HH_'K22O@<1QJSEB$52Y"U\4^,_P!E;]IKP'-J>K>,?V?/
MC1X=T/PQ<R?V[XDU+X:>,(?"VG0VDGE3WDOB@:0WA]]-#,GEZG#J4FGSI)')
M!<R1R(S?WOTFU<D[1DE23@9)7[I)[E?X?3M0!_&Y^ROXZ\8?#[7-/\1>"/$F
MJ>&=:ACB@%]I<ZJ9;1[B"XDLKVUG2>PU/3IKBTMIKC3-3M;S3;J2VA^U6DPC
M4#^J/]G'XU/\:O`<.K:MI]GI'B[2#!8^)].TZY%QILLTD9:RUS24EN;G4+32
MM<CBGEAT[5'DOM)O[74]'>^UJ#3[?7]7W?B%^SW\%OBG<2:AXY^''AG6-:E^
MP+)XDALO[(\5O%IC,]A:OXKT5].\126%L7<+ILFIMI\B.\4UK)$[(?G7PY\"
M[K]FWQ7IWCC1?$UMJ?@:P>RT?6KWQ//I.CZMIOA35UTZPUYO$.N)H\MG>VEM
MJT$'BZ,Z%8>%Q=7NFZ%H^H1VVEV6I:Y,`?=U?QG>'/\`E;]\<?\`8N0?^N[_
M``E7]F/^?7]1Q^5?PJ?MY_&O5_\`@FI_P<6>(_VZ_C9\(/B7JWP1\5>&=+F\
M`:KX9TRQ\OX@PO\`LC^$_@QK9\+:MK-_I7A^[O/"GC1)[;Q+I%QJUMJVF64=
MMJ$EFUIJVBRZC^C>'-*IB:_%V!H1]IB\?P3G.$P=#FA&>(Q,\3ETXT:?/**<
MW"$YVO\`#"<GI%GQ7&M2&'I<.8NM+DPV#XIRS$XJKRRE&C0A2Q:E5FH1E)03
ME%-VWDENT?W5UX?XU_9P_9O^(_Q&\*?%SXB_`CX)>._BWX#.@_\`"#_$[QK\
M+_`?BCXC>#&\-:Y<>)?#)\*>--=T*^\3>'6T#Q)>7>O:$=(U*S.E:W=7&JZ?
M]GU">2X;^;+_`(BV/V.O^C;_`-I?_P`!_A;_`//&K\^YO^"B/QR_X*R?\%BO
MV)_$_P"Q-I?[47@CX-?#R]^`=U\>?AQ/XRN?#?A`>$?A=\>/$/Q!^*7Q`^(&
MF^$_&-SX"_X1J[\!:YH_A>*3Q/=#4O%VM6^E>`M-L-5UG5_"^C:I&"\.>*J/
MUFOF5&KD&#PN`Q>(KYC6JT72C3HT7*5"7L,4I_[1&]-7]QMI23NDZQ7&G#]1
M4*."JT\XQ.(Q>%P]+!4X5%.4JM:,553JX>4;4;^T>FRWBKM?U<_\%8_^49O[
M=O\`V:W\9/\`U"M6KY:_X-V_^4/'[(?U^/W_`*U#\;*^WO\`@HS\/O$WQ5_8
M&_;+^'7@O1M5\1^,?%_[,WQJT;PGX<T*PGU36_$?B6?X?:^V@^'M(TZU26YO
M=3UW54M-)L;:"-Y9;J\B1%9B`?Y*?^":_P#P<$?L^_\`!/3]BWX0?L=?%OX`
M?M#:I\3/@K??%?2O&D^DZ3X)TVQMM8\2_&KXC>.?[+6Q\2^,]%U^TO='LO%%
MII>KVNJZ1IUU:ZS9ZA:^0T4,5Q/T9'E&8Y_P'C\MR?#2QV.H<6X+&U<-3J48
M58X5Y/BZ'M[5:E-.'M9*G=/XM.C.?-LQP>4<88+&YE76%PE3A[&86&(G"I*G
M+$/,,'5]BG"$_?\`9P<[6^'6Y_=#-_JI?^N;_P#H)K^3[_@W4_Y/6_X+??\`
M9R/@O_U;7[7%3M_P=K?L<LK*?V;_`-I@!@5)%O\`"W(!&#C/Q&QG%8W_``;(
MR^(_B!\5O^"I7[2J^!O&/A?X7_M#?&/X?^*_AKK?B;1+JPL?$`/C?]HWQ+KV
MD:5K")-H>MZIX.M?&WAFU\51:'J>I0Z3>ZO8133[;RV:;LPW#F=\.<'<;RSO
M`3RY8W#Y#2PGMJV&<L35I9YA:U2G1C3K3E.4*47.2MI'5M(YL7G65YWQ'PI3
MRK%PQDL-BLTJXCV<:B5&G+*ZT(SJ.I"%HRFU"+U3DU'=H]M_X.M_^4<'PV_[
M.Z^&_P#ZJWXVU\]?\%+?@Y\1O^"3/[9G@#_@LK^ROX836_A'\2KZV\`_MP?"
M73-%-GIS0^.;O0[76/&8U#1I;.+2HOBQK5GI.I-KNHP6MMH7[1FE>%/$OB"Z
M\<Q?%"^\)0?0G_!UN1_P[A^&PSS_`,-=?#<X_P"Z6_&W_$?F*_H:\9_#;P)\
M:/A#XE^%?Q(T"S\7?#WXD^!]8\$^,?#]S-<PV^N>%_%&D3Z/K>G"^TZXM=1L
MC>Z==SPQZAI=[9ZC92,EWI][:W<,-Q'E@,]>2<+\)U:E/ZWEN*S/BS!9QE[E
M[F.RZO3X?5>B[-<M:/*JV&J)J5+$TJ<T[1:>F+RK^U.).((0F\-C*&79!BLL
MQJC>6$QU">9^QJQNK2IN\J6(IN\:M"I4IRU::_FV_P""MW_!0G_AM#PE^S3_
M`,$X/^"</C[PY\0OB+_P48T+3=9\5^/-)UKQCHMK\/?V==4"ZO=P^)CI.EV^
MH:*?&&BZ%XVN/BUX6U1+[QCX3^$_@3XA^%O%OPNN+WQ_X="?%WCK]ECX<_L5
M?\%X_P#@CG^S+\*X[L^$OA=^RUX0T[^T]0GN;C5/$WB/5/'O[8NO^,_&&JO=
MW-V\.H>+_%NJZUXCN--M9DTC1#J*Z'X>L]-\/Z;I>FVG[;_\$G_^"+?PN_X)
MA>+OCU\0=/\`'.I_%7QS\3M<O?"_@3Q%K.G:=87O@/X!66K+K&A>![I[*PM/
M[5\8:_J4.F:I\3/$5G_9GAOQ!>>%_!J^'O"'AA=&U&77?S@_;^_Y6=_^"97O
M^SYX0QGO_P`5C^UTO'K@\<?C7JY+F>54ZV9\.\.U:M7),%POQ1C*F+KP=&OF
MV9XC*JB^LUJ3C3<8X+#RA@,+3=.*2A5K13^L7.#,L!CZE/+LZSFC3IYKB<_X
M<P\,+1J*O1RW`T,UP[]E1J1NG+%5>?%XFIS._/1I-J-!'[^_\%*?^4='[?7_
M`&97^U-_ZHWQU7\77_!$3XT?\%HOAU^RS\0=$_X)R_LE_`'X\?!:[^/OB?5/
M%/C#XK>(M!TG7M-^*$GPZ^%5GK7ANRMM5_:6^#DSZ1:^$[/P/JD$Z^%K^)[W
M5M0C37[EX9M.TS^T;_@I."W_``3I_;Y4`DM^Q9^U*`!U)/P-\=8`'<GTK^+[
M_@B!_P`%N_V5/^":G[*WQ!^!_P`<_A]^T'XM\5^+/V@/%/Q6TW4?A-X5^'&N
M>'H?#NN?#GX4>$;6SO;OQA\5_`FI1ZS'J7@75IY[>#2;JQ6QN=.EBU*6>6YM
M;3#@2EBZ_!_$M/`Y+A.(,2\VRJ4<MQM.I5H5(JG+FJ.G2Q.%FW3^*+59+1W4
ME=#XOGAJ7$O#]3&9IBLFH++<TC+'81J-:$W/".-+FEA\3%*I9W3IW;4;-'[%
M2_M4?\'4$44DK_\`!.#]C9EC1G81>,?",TF%!)\N&']NUI9G&/DC1'9VPHC<
MG:?*?^#4?P[\(K'X>?MD>)-&^(/CC5_VA-=\9?"73_CU\,_%GP]B\$:9\/+;
M1HOBG=>`[_POJ=KK&N6OBZV\5ZGK7Q$L]4N+EO"NO:-J/A)M-U+X?:'IIT#Q
M'XR]1U?_`(.SOV`8=*U*;0O@5^V'J&MQ6-U)I%AJ_@WX+:/I5[J:0.UC9ZEJ
M]G\=]<N]+L;FZ$4%UJ-KHNL7%E`[W,.EZA)$MI-Y=_P;`?#_`.-VO>(/V]/V
MNOB9\--?\`^"_P!ISQQ\/O$7P_U._P!%GT3PWXUU-/$'QI\3^.+OP-%=QVUQ
MJ7A7PO=^,='T6UUZULFT&\OKV_T;3=4O-3\.^(K/3_1S#"YGAN".+?[6X:RO
M@]3_`+$^JK+J;PTLZJ4\PA*I@JM+%8W'5*T:,']:A+#^PG3G#]Y.=)5('+@*
M^!K<4<.O+L\S#B5P_M18AXZ]1992G@5'ZU1G2PN#ITIU9)8>2K^UC4A/DA&%
M11D>;?\`!WU_R)'["'_8U_M">_\`S!_A#VY_D:^F(OVK?^#ISRXS%_P3>_8Y
MV;%V[O%GA8/M_P!H/^W8&#=<@CKZ5\S_`/!WS_R)'["'!./%?[0A./3^R/A"
M/YD#/09&>HKZFB_X.Q_^"=B(%/P6_;3)4`?\D\^!N.,]/^,BAGO_`/JQEY;A
M\TQ'`?"*RSA3+>*.3$\2>W684*];ZCS8_#^R]E[#'8)Q^LVG[3F=1/ZO3LH6
M?-GC:^`P_&/$SQ_$.89`JE#(_8_4IP@L9R8.?M%4Y\'B[_5^:');D_C3OS.S
MA^[G[%/BS]JKQQ^S3\//$_[;/PV\&_"+]IG4IO&8^(_P]^']W!?>$=`2R\>>
M)[#P:=)N[;QW\3+:;^U?`5KX7UJ_,'C;6HTU/4;R,?V<4.DV/'_\%+?^4<G[
M?W_9E'[5'_JB_'=?BN?^#LK_`()UX/\`Q9;]M/\`\-Y\#/\`Z(NOVD_X*3R+
M-_P3@_;[EC8/'+^Q-^U,\;+R&1_@5XZ92".""#D$$@YX-?GN(R3.,HS[*L1F
MV4/)X9CF].KA:"CR8:"AC*%2I1PR=6M.-'#QKTX0C4J2FJ;A><W>1]KA\WRO
M,\HQ]'+<Q>92P66RIUZTE/VTF\+5A"K6E*E2C*K6=*<YN$4G/F:C%61_%M_P
M10_X*L_&+]A;]ESX@_"7X>_\$^_CA^U?H_B3]H'Q5\1;CXA?#.\\4P:'HVHZ
MK\.?A7X:G\&W4>A_";QY;'5M.MO"-GK<[/JUO/\`8O$%B'TZ*-8[FZ^QOBO_
M`,''7Q!_;A^`'[1G[.'P7_X)I_%[Q;K_`,5O@O\`$3X3ZCJ7@7XAZW\2+CP1
M%\4_"FM^`X/$NJ>'_"OP,N;RZ33;C5I+FTTF>YTA=;N[3^RDU;39)3=P?;G_
M``:<%6_X)W?&M201_P`-I?$+C()P?@=^SJ1QSP2#U&#CUK(_X*W_`/!-OXM_
ML[?%>]_X*Y_\$QI[SP!\?_`;7GBO]H[X1^%;&5O#_P`9O#K75M?^,?'=MX6L
MA#::QX@U>.-[WXQ>"W$6F_$JSM3\1=-.E?%G1M9U#XD?IN88O@S%<>9U@<RR
M*A1S-9@_J&:U\ZS.E@L1FM/V#H4\?2HS5/"4<1-1I*K3C5A2J\L9TI0FW3^&
MP6&XGH<(Y3BL#F]:I@/J-)8S+J.5Y?/%T<!4I6K2PDZM-SKU:/O2]G5E"=2F
MVX3=1*,_HG_@VG_9O^.7[-7_``3\\5Z)\>_AGXN^$OB;XC?M*?$3XDZ!X.\?
M:#JGA3QG;>$SX*^&'P\M[[Q#X4UVUL->\-W%_P"(/A[XBET[3]:L+.[OM"&D
M^(;6.;1];TNZN/R^_P""T7_*Q%_P29_Z^_V(/_6Y/B97]`/_``2N_P""J/P9
M_P""F?P<7Q#X;:S\$_'#P78V$/QC^#-W?1R:GX<U&X14'B7PQYL[7>O?#W6;
MKS%TG7#&MQ8W0DT76XK;4H4:[_FG_P"#AKXMZ-\`_P#@MA^P#\=_$.G:EK/A
M_P""?PT_9C^+6O:1HJVKZQJNC_#?]K7XQ^,=5TS21>W-G9?VI?6.CSVUA]LN
M[6U^URPBXN(8B\B^+PX\UQGB7GLLTP3P.:XK!<0.K@-$J5:K@9>QH4I2DU4C
M*'(J57G<:R:J1ER237I9XLOPO`F6+`8EXG+\-B,C5/$M7E.E2QM#GG4C%>Y.
M+352GRQ=*2=.24HR/[JJ*_E"_P"(MC]CK_HV_P#:7_\``?X6_P#SQ1_*OJO]
MB/\`X.)?V;/VY?VH/A?^RQ\/_@E\;_"/B[XIOXQ32O$7C./P%%X;TT>#/`'B
MOXA7YU!M$\9ZQJ9:[TWPG>6%DMM83;K^ZM?.:*W\V5/C,5P!QA@<+7QF*R/$
MT<-A*%3$8BJZN$<:5&C!U*M1J.(<FH0C*348N5EHF]#ZJAQAPUB:]'#4,VH5
M:^(K4Z%&G&&(O4JU9JG3@G*BE><Y**;:6NK2/W1^*_Q.\'?!7X9_$#XN_$/5
MTT'P'\,/!?B;X@>--:>UOK_^RO"OA#2+K7-?U%-/TJVO=5U&2STVSN)HM.TN
MQO=2OY52TL+2XNYH89/Y>/\`@A=\/?$/[:W[5_[5_P#P6D_:(T;3]*UOXF^,
M=;^%_P"S-X8\00:9--X.\(:98Z?H6LZWX?O+GP%X;LM8B\&^!=,\'_`7PO\`
M%+PC>6.H^)+K2?CWIOC;33K6IWD\VS_P<2?M!>/OCMXM_9R_X(\?LV&WUCXM
M_M2^,_!7B;XN&.UU'4=/\.^`[3Q0DW@#3/%JZ7X0\4W^E>&1XI\/WOQB\?:_
MH,MMXB\#>#/A'9ZOJ6GWOA/Q3<QW?1K_`,&FO_!/DJOF?&G]LIG"@,T?Q&^"
M2(3R3L0_LX.57))"[VQGDD\U]#DN$R?)>%:]3.LSQ&4YAQC2]GA*N$R]9EB:
M/#V%Q%/V\726.PDJ*S?%QC>4FXU<)A(\CE[2HH^+FF)S3,>(*,,KR^CF>"X<
MGSXFGB,;]1I5,XQ%%^Q<*CPV(]K++L--R:Y+0KXE7<:E'W?EG]I3Q!'_`,$4
M/^"WFA?M2V.I"T_8L_X*)MKMQ\:+:+4-5U/3_"WC#5M<TRX^+_B.:PBU_P`8
MZYJ&I>!?B+KN@?':WU:#POIT?_"'_$WQO\'_`(::/%!87\L7]E\;B1%<!E##
M.UQM<>S*>58="#R#P>:_D-_:._X-1_V:-&^!'Q7UC]F?XJ_M.:]\?=$\$:YK
MOPG\,^/_`!A\&M<\(^,/&6BVIU/2_!&KV]M\+_A:=/'C9K1_"=CXDNO'6BZ;
MX1U+6;3Q5J\>L:7HUYH6I_:G_!N!^WL_[5?[%\'P%\=:@TOQJ_8]@\/?#/5$
MGC\JXUWX/365Q;?!OQ$Z6^A:/ID%UI&EZ+K'PPU&PM[S7]=8_#RP\8^+M134
M?'=HDM<58?*\[X?R_/<FQ]?-,3P]3PF29]7Q&`>78FKA9*7]D9C5P[KXA3Y(
M1>7UL1[>M4KU(493<'%P2X=KYAEF<8O*<SP-/+J&;RQ&;931I8M8RE1K1=/^
MTL'3K*C048RG-8VE15*G"BIUHKF<N:7Y??$'PIX:\>_\':=SX!\::'I?BGP5
MXZ\$^(?!_C/PKKMC;ZIH'BCPMX@_X)K>(].UOP]KVDWD<UEJNCZK8S2VM_IU
M[#-:W4+M'-$ZG%,^/_[/G[3G_!N?^TM?_M=?L?V'B7XK_P#!-WXJ>(-(L?C)
M\']6UC4]5B^&SZKJHM--\*>+M2D6YN-/@M+JZ73_`((?'>]AO[_3[[4+3X6?
M%*ZUS4M8LK[XO]%J3*?^#P'PZP((_LZX&>V?^'<NO)CZ[_EQ_>XZU_9'XK\*
M>&/'7ACQ#X+\:^'M%\6^$/%NB:IX:\4^%O$FE6.N>'O$?A[6[&?3=9T/7-&U
M."YT[5=)U;3KFXL-2TV^MY[.^LYYK:YADAD=#VYQQ%/):G"E&M1IYEDF8<`\
M.T<WRBM+_9\92C/&6J0E%.5#'89VJ8;$T^6K2J12O9M'+EF21S.'$-:C5E@<
MTP?%V;5<NS*E%.KAJKI8)3C.+:5?"5U%4\3AIWA4ALE-*2_DZ_X+W?M:?`_]
MMC_@C)\,OC]\`/%L7BCP1XE_:?\`AI:75M<)#9>)?!_B6Q\%_$@ZSX+\;:$E
MS=3>'O%>B//";S3IIIH+NRN=/UW1;W5O#>L:-K.H?T&?\$T_^4<_[`W_`&9=
M^R[_`.J1\#U_%-_P6,_X)3?%S_@FEX8^-GB?]F^VU#QY_P`$\OVA]7\%/XF\
M-ZO<^(_$.L?LN_$/0/&.G:MX&N]4E75$;4-(+WFO_#3X9?%WQ/'KS6GAOXC^
M)?A9X]5?'^M^`O'OC[^UC_@FD0?^"<W[`V"#_P`87?LNCCG_`)HCX'_EW]#Q
MUKFXMPN583@C(HY+C_K^6U^(<UQ6%G4Y8XO#TZ^"P7^R8^G'2GC,-*$J=2UH
M58J%>FE3JQ2UX=Q./Q7%F:SS/!O!XZCD67X;%1A>6&JU:6,Q7^T8.J_XF&KT
MY0JPO[U.4IT9WE2<G_-'_P`%K/\`E8`_X)$_]AS]CW_UM#Q17]FHZ#Z#^5?P
MZ_\`!Q%\6M$^`7_!9'_@G;\=O$NG:KK'ASX+>!_@!\6->TG0DM)-:U31_AS^
MU%X^\8:GIFD+?W5E8MJ=]9:1+;6(O+RUM?M,T1N+B&+=(OV)=_\`!VW^R+%:
MS/8?LS?M'75VD>8+:\D^&6GVTKC&$GO8?&^IRVR8R3(EA=-D8\KG<O3FW"^?
M\0\-<!U,FRVKCX8?(\52K2I5,/!4ZDLRQ$E"7MJU.TG'7M9[DX'/LHR;/^+Z
M>9XVGA)ULTP52E&I"JW4@LIPD7*/LZ<TTI1:]4?MI_P5N\#>#OB%_P`$S?VY
M="\<:;;:IHUA^S/\6?&]E;W4TL$<7B_X8>#]5^)/P\U%7AEA+W&C^/O"OAO5
MK*"1GAGN[.&"2*993$_Y:_\`!MS$/VAO^"1%[\'?C7X0TKQ!\,O!WQR^+GPU
M\(:3J>CM#;ZUX*OIO"GQ>DU?[6X62ZU;2OBI\0O&<^B^)]+EM]0T'4M&TTZ9
M>6FL>'X[J+\P?VD?^"C/_!1O_@NO\-](_9'_`&./V'O%?P?^"7Q-\9)I/Q9^
M,6MZOK?B[P9K.E>&KW2_%>CZ3XF^+]U\//!_@7X4^'M'FTK_`(23Q=H>FS^*
M_'OC>XLM`\)^$9[A;_4?!OCW^M3_`()__LD:-^PM^R!\$?V6=$\0:AXKB^%W
MAW4DU?Q-J4=O!/KOBWQAXEUKQ[XVU&UL[:&*/3M&F\8^*-='AS2I9-0O-(\/
M+I6EW^LZW?6ESJ][YF:8:MPMP3'(\SKT:6?8WB:AG%#+L/BZ.(Q&5X?"X'ZN
M\97GA:M6GAL17G.-.G34U5E!<ZE>E5A2Z\!7IY_Q2\WP%*K/*<+D=;+*N-K8
M>I0HXZO7Q<*ZP]&.)A3E7H4J2G-SC"5/GF[-*47/I/@=^QI^S]^SOKW_``E7
MPV\-^+YO$]OX'TOX8Z-XD^)?Q=^,'QOU_P`(_#?29;.XA\`>`M:^-7COX@:G
M\/\`P;?WFF:-J'B#PUX*NM!T?Q3J/A[PQ?\`B6TU:[\+^'9M,^HZ**_-ZM:M
MB)^TKU:M:IRQA[2M4E4GR07+"//-RERQ6D5>R6Q]Q3ITZ4>6E3A2C=OEIPC"
M-W:\FHI)R=E=[NRN]`K\E?V[_@-<Z1;ZM\3?#=E/=^'=<NYIO%.GP:?9+:Z!
MJE]'!'<:BHT^U@<Z9XDO3<7NIW&IK<3#Q'>W;2ZA)!J^G6%C^M55[JUMKZVG
MLKVWAN[.ZBDM[JUN8TFM[FWE4I+!<0R!HYH)D+1S0R*T<L;-'(K(S*<BS^42
MX_X*$_M8?!&>!O#WQ/N_%&DV6HRZE/X?^(]E;>-[/4]R11OIUWK>J#_A-;/2
MBD,?EV.A>*]'CMFWR6I@>65G].^''_!>7XNP'4(_BA\!_ASXL=SC3'\!>(_$
MWPY6T4,`WV]/$*?%,ZBY'W6MY-+1223&XP%^M/VU_P#@D_)\0AX@\=?LUZI8
M:/KEZUYJ=Y\)_$-Q#I_AFXF%A-<36_@77A`6T"YU'4H(UL_#WB%V\,V]WK%S
M]F\0>$O#^G66E1?S@_$GX"?&CX!^(CX>^,GPS\7?#S4IKK4[33Y/$.DSP:1K
MLFDRVR:E+X8\10B?P]XKL;-KRT$NI^&]4U73L75LRW3+/$6`/Z!="_X+FVE_
M?1QZK^S->:?I[!"]SI_Q@MM5NUW,0VVQN/AAHT3[5"D?\3"/.3GJ`GZ?_LD_
MM?>%/VN-!\5ZWX8\)^(/"G_"'WND:?J5MKMQIUUY]SJUI<W2_89K"5O,A@^R
M2HTD\-L[[HV$2[F5/XN-&^^G^ZG\Z_I+_P""*O\`R(?QR_[&GP=_Z:=:H`_;
M>BCK2%@H))P!U)X`]\GL.I/0#D\4KKNOO`6N(^)FK>`-!^'/CW6_BO<Z!9_"
M_2/!?BG4_B-=^*XX)?"]MX$L-!U"[\7W'B2.ZCEM7T&'P[#J4FL)=1O;OIZW
M"3(\;,I\3^*_[9G[./P?T[4;SQ'\2='UC4--U#7-$G\.>"3+XUUZ'Q)X?M;J
MXU#PWJEMX<34+7PKJPFM6TL-XTO?#6EP:O/:Z=?ZG937"5^.,/[87Q<_X*5_
MM>?"W]G3X:^&?^%??LP>#_%7ASXP_&6+6K;0]>\5^-O!7PH\5VOBB/1O'=M<
M:M;Z+!X2\;>*(_`?@2Z\&>&%\2W]C<ZQ=^(M5UCQ3X;@OM+TKZ#+>'L?CH5<
M75I3PF682E/$8S'8A>RA"A27-.-!32EB,14_AT*=*$^:K*$963;.:OBH4E&,
M6JE:I)0ITXN]Y2DHWE;X80;4IMNZBFTFT?T7KC:NW.W:-N00<8XR"`0<=B`1
MW%(44YR,YP#GG(!RO7T))'H2?6E10JJHZ*H49)/```Y))/U))/<U^0'_``4R
M_:2\7_!#XY_L$>!8?VD_&'[+_P`(/C=XZ^/6B_&CX@^`_!OPL\7^*UTWP-\$
MM9\:^!K;2E^*GPA^->E:9Y_CFRTG3[^>Q\&7-Q<:9J5Y%+-:[8-0L/-R_`5L
MSQ<,%0<%6G2Q59.<:LX\N#PM;&55&-"G6K3G*E0G&E"G3G*=1P@E[UT8O%PP
M=#ZQ4C.454H4^6#IQDY5ZU.A#WJTZ5.*4ZD7*4YQ48IM[6/U]\J/^XOY4>5'
MQ\B\9P=J@\@J>@'4$@XZC@\5^4O[#/QV^-OQ!_:$^-/@&V^('Q5_:;_9'TKX
M<?#WX@?#G]J#XT?`N#X">+K'XD^)=5\1>&?$OP1T2?1_@]\"?`?Q]\&6^F^#
MH_B7IGQ.^'OP[M(_"$OBT^"_%/B'Q5)>^'KO3OK?]N;XA^,?A%^Q7^UW\5_A
MYK!\.^/_`(8_LR?'CXA^!M?%AIFJ'0_&'@KX6^*?$OAG6!IFMV6I:-J)TS6]
M,L;T6&K:=?Z9>>1]GO[*ZM9)8)-,1E=;#YA1RZI.C.M6^JJ,E[10C];4'3C5
MA6HT\11G'GC[6E5H0JP6O(XRBY9TL=3JX.>-4*L:=)5YR@_9RG_L[FI\DJ=2
M=&I=TWR3IU90EI[Z::7U.>>#T-,,<9ZHI_"ORO\`V5_^"C_PI\6_LL_LZ^*?
MBSX@^,NM?%'Q/\`_A)XB^).N:?\`LF_M(RZ9J_CW7/A[X?U/QAJUC>^"?@>/
M!,MA?^(;K4;RVN?"+CPLUO,DN@L-)-H:^L/V'?B)XP^+W[%?[(7Q8^(6L?\`
M"0^/OB?^S!\`_B'XXU\6&EZ5_;GB_P`:_"KPIXE\2ZO_`&7H=EINBZ9_:6LZ
MG>WO]GZ/IVGZ79>?]FT^QM+2.&".L9D^.P,*]7%494HX?%QP5YTZU/VM24:\
M^:@ZE*"G22P\N9WC)<]+W/>;BL/F.$Q52E3P]6-657#RQ-Z52G45.$)48\M7
MDJ2<:EZ\>56:]VI[RM[WT_Y4?]Q?RI1&BD$*!@8&`!@<''`Z9&<=,\]:^>/V
MK_VA]'_98^`7Q!^-FJ>'M<\:7WAFPL=,\%?#[POIVNZMXH^)WQ2\8ZM8^#?A
M+\+/#-AX;T'Q-K$GB#XF_$O7O"O@32;FWT+4+?3+SQ!%JVJ1Q:38WUQ#\D?L
M3_&+]ISPG\5/%G['O[='BOPUXV_:"3X:^&/VC?AO\2O`G@U_#'@/XC?#7Q'%
MX>\.?%KP;HYT[2;+1/[6_9P^-U]<^"(Y;Q=(\2^)OA+XW^"7C#7=(G\3:OXM
MU`S1RS$5\!B,P@Z7LL//E5.4I>WKQ@Z2Q53#4U!JI#!+$8:6+]^,Z=/$0JQA
M.G3Q$J-5,?1HXNC@Y>T]I64??BDZ5*4_:?5X5I<RE"6)]C7C0M&492HRIRE"
M<Z,:OZ?LBM]X9&<X.,9'ZC\#ST/%*JA0%48`X`'``[`#L!T'M0?ZC^8K\#OB
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M-&LVGBD>(;'5/`<GPLUW4=#TWQWXITGX>^*_$_PQF\1^*Y_AWXM\;_#:P\'^
M,_%O@B;6GD\*^)=?U70CIVB_8/['L?`_^"G_`,1?VL?`?A']F?2_V,/&&A^%
M?C7\1OVE+OPQ8Z9XG\*>%?%OAKXFZ=X,_9@_::^.=K\&_$,7BJXTR/PWHGQ3
M\6?"'PMX.U7QMH'B+PIXG\)6&ISZQI7B*T%O<6]W5#*JU?-I92L1A*=6%?$4
M)XJ=5O!16&C4G6K>WA"3>'4*4Y*HH6Y5S-)7LZN/IT\#3Q[H8F<*D*%2&'C2
M7UKFKN"IT_93G!*JI3491Y[7NDY*S?Z<LJN-K`,IX(/(((((.>H()SZ]Z;Y4
M?]Q?RK\QOB[^WI'XQ_8<^%OQL_94C&K?&3]L)_"/PC_9?\,>([&[N[CPS\<_
MB3'J>EZK_P`+0L_"FB?$*ST6W_9A30OB'X]^/-C<6]_I>BZ5\&?'N@3:FM['
M;R2='_P2;^,GQ;^/O[!OPA^*/QU\<2?$GXJ:MXI^/OA_Q/XXE\-^%_"$OB&/
MX>_M%_%GX<^'[J3PWX,TC0O#6ER0>%_">BV3Q:;I=OYK6IN;R2[OY[J\N*JY
M-C</EU;,JZA1IT,SAE53#U'..+^LRIXF<IJGR.'L:4L+6HSJ.JFZT94Z<9^S
MK.G-+,\+5QE'!47.I.M@)9A"M!1>'5&-3#TU!SYU+VTUB*56,(PDE2Y9U)0Y
MZ2J?HOY48_@7_OD'I]:545,E5`+8W''+8&!N/4X'`ST[5Y+\>?C=\//V;O@W
M\2?CM\5];A\/_#[X5^$-9\9^)]1EEMHYVL-'MFE33=+ANI[=-1U_6[QK71/#
M>C0RB]UWQ!J.F:+IZ2WU_;Q/^:7[&?[1O[6/A#XXZ/\`!7]OC4=&L?$/[87@
M'Q%^TS^R[H]KHW@O0'^$%YHVIS:C\5_V%=4U?3+KP_KGQ/\`&?P'^'&O?##Q
MIH_C2Y^'RZOXPLYOC1=WOB76].^'UO<KEALLQ&*PF*QM.5%0PR=J<YN.(Q2I
MP]KB?JL%%^V6!PZ6)QEY15"@XU-6TC:MC:5#$4,--5'*NU><4G2H<\U3HO$2
M<DX?6*S]AA[1DZM52A'X96_8=D5\%@#CU`/7'J/;MBF^5%_<7\JD/'-?F1:>
M+OVC_P!K?]H?]H_P%\-_CA<?LT_L[?LM?$+PO\'[CQA\*_"/PY\9?'SXL_&Z
M3X5>&OB;\0+2ZU/XZ>`OB-\,/A]\)O!VB?%KP'H-MI%I\)?%?C7QEXNTC6M:
ML_B/X4\-VR^'M<RPF#EBOK$O:TL/1PU'V^)Q%=U/9TX.I2H07+1IU:U2=2M5
MI4X4Z5*<O>=22C2IU:D*Q&)6']C'V=2K4KU?94:5+D4YS5.=63O4G3A&,*=*
M<Y2E-*T5&/-4E"$OTR$<1Y"+^5/*KM*X^4C&.V,8QBOF+X-?![X]_#'QYXBO
M/&G[67C']H/X5:UX3TFWTKPI\7/A3\&-$^(WA+Q]8:M?R:AX@T3XD_`?PC\%
M?"UWX*USP_=6FGWO@?Q)\(=?U^WUW3+;7M,^(^GV$VH^&M0^A/$MS-9>'-?O
M+9_+N+31M4N;>0JCB.:"RGEB<I(KQOLD56VNK(V,,""16=6C&%;V-'$4L3%N
M"C5I1KPI.4U%VMB*-&K>#ER3?LN5RB^24XVD]*52<Z:G.E5HRUO3J.DYKE;2
M?[JK5AJE>/OW46N90ES16RJ*N=HQGC\`2<?F3^9]32D`C!&1QQ]#G^E?SY?L
MG_'3Q%\</@3^S?XN\;_\%)?^"B6F?%GXO_"GX2>(/%NG>$_V*O@9_P`*XT[X
MA^/O"6@7^N6/AOQ/=?\`!,/7O#R^#++Q)JMU;Z1KUUXYUC1TT6.WU&X\57]D
M&U:3^@U3D`YS^&._I^G^-=>:956RC$2P^(JPJ554K0E[.ACJ,>:A)4YR4\9A
M<,JB<K<KI<ZY4I2:YHWY,NS&CF5%5Z,)0@X4IQ4ZN%J2Y:T.>'-'#8C$>SDE
MO&;B[Z*]I6:(XP00BY4DJ<#*D@J2/0X)'T)'0F@QQDDE%)/4D9/YU\4_#'XI
M^//$?[>_[7/P@UG7C>_#OX7?`?\`8[\7^!/#ITS1X!H7B+XJ:Y^U):>/=1&J
MVNGP:WJ3:];_``[\&Q?9M7U*_L],&D$Z-;Z<VHZJU]U?@WXA>,-2_;<_:$^$
M]YJ_G?#_`,&?LO\`[(WQ$\-Z`+#2XAIOC+XG?%?]MCPUXXUDZI#91ZU>'7-$
M^$7P]LOL&H:C=:7IO_"/_:=(LK"[U;7)]3B>75X>WO.D_JV7X+,9\LY^]A\=
M'`RI0A[BO4A]?HJK%\M.+A5Y9SY8<^D<;2E[*T:G[[&8C!1NHZ5<,\4JDI>^
M_<E]4J<C5Y/FAS1C>7+]5>5'_<7\J/*C'(0`]B!R#ZCWKB?B5X1UWQUX+UCP
MMX;^)?C;X0:UJ3::UE\1/AU8?#G4_&/A_P"PZK8ZC<#1[+XL^`?B?X`E_M:U
MM)M$U`Z[X'UIHM+U*]ETEM,UI-.U>P_*7X;>`_VI/%W[8G[4?[/VJ?\`!1K]
MK.+P7\%/A-^RWX]\(ZE8?#K]@&'Q1>:M\;=4_:'L/%EKXBOKG]B*[TF^T[3T
M^$7AV3P['INBZ/=6CZAK8U.[U=9[`::8/`+&4<76>.PN%6#I>VJPQ%/&SDZ4
MJV&PRG'ZMA*]/WJV*A#EG.#?+-M*/*Y3BL:\-5P]+ZIB:_UJI[&G4HO#*$:B
MI5JSC/VV(I3C:E0F^;EY&W",9.3Y5^R'E1;M^Q-V,;MHS@]L^G/3I^%25'"C
M1PQ1NP=TC1'=5*AV50K,%9G*AB"0I=R`<%F/)^"_@=\9OB5XN_X*`_M[_!3Q
M#XC&H?#+X-?#7]BKQ#\-O#7]C:!:'PYK'Q9T3X\W'Q`NSK5CI5MXAU@:_-X*
M\,N+;7]6U2TTG^S2NAP::M]J(N^>AAJE>GC*L)04<%AHXJKS.2E*G+%X3!*-
M.T97DJN,I2Y9.,53C4:ES*,)=%2M&G+#PDI7Q%1T862]V4:%;$>_=JT5"A-+
MEYGS.*M9N2^^*8$1?NKMSP-HQ@=,9`Z=.#P.U>2_M`?%[2OV?O@3\:/CQKNE
MZCKNA_!7X3_$3XM:SHFCM;)J^L:5\.?".K^+]1TO3'O9(;./4+^ST>:ULY+N
M6*V2XEC:XDCB#,/C'X6_`K]MGXK^"M)^)GQX_;5^+GP(^(?CW2M`\3:G\"OV
M</AO^R4GPP^#AO?#FB22_#NUUSXW_`;]HWQ[XW\0:'J<>HIXM\<W/Q'31/$F
MNW.H3>%/#'A/PRFE:/;[8?`NMAY8JKB:&#H1K?5H5,1]8;K5E"%2I3I0PU#$
M3?LJ=2G*K.<84H^TA%SYI\IE6Q2A56'A1K8BK[/VTH4O8VIT^9PC.;K5J,%S
MR4HP2DYRY)M1Y8R:_2<1(#D*,YSG`ZYW$].I/)/4DD]:DKR_X+^&_BCX0^%_
M@WPO\:?B7HWQC^)NA:1'I?BGXH:%\/+;X4V7C>YLY98;/7[CP!8>)O%NE^']
M;OM-2RD\2QZ'JT'AR^\1_P!JZGX;\.^#]`O=-\(Z'Q?[57[0FB_LM?`+XC?&
M_5O#VM>-;SPEI5G:>#/AUX8L=:U/Q5\4_B=XLU:P\'_"KX4>%K'P]H?B76)?
M$GQ/^(VN^&/`NB36N@ZG'8ZAKT.H7T`TZTNY8\(8>=;$PPF&MB:E6O'#X=TE
M.,:\YU%3I.FJT*4XQJMQ<%5A2FE)>TA!W2UE5A2H2Q%5.C"%)UJO/R\U*,8<
M\U/D<HN5-)J7+*4;I\LI*S?T"T:.064$CH2,XSUQZ9``/J/I3@`HP.!S^IS7
MYB?L6?&']ISPK\6O&/['_P"W)XF\,^,OCV_PW\-?M(_#+XC>`O"-SX>\!>/?
MAOKL/A_PU\9/`VC2V/AO2=#_`+3_`&<_C?J#^%+:74IK+Q=XE^$7C_X*^*M?
MTJ3Q+J'BN^/Z=G^H_F*TQV#G@*[HRJ4:\73IUJ6)PLI3PV)HU:<:E.O0G.%.
M<H23Y7SPA4A4C.E5A"I"<5&%Q,,725:,*E.5Y4ZE*M%0KT9P=I4JL5*2C)64
ME:4HRA*$X2E"49-K1HQRR@GIR!_G_/'4Y!%&.0B@^N.1]/0U\K_L[_$+QAXU
M^*O[<'AOQ-JXU+1?A!^U!X5^&WPZL1I^EV*^'?!=[^QM^R7\5[K1A/IUC:7.
MJ^;X_P#BCXZU\ZCKDVI:LO\`;G]EI?KHNF:/IVG_`%76>)PT\)5]C4<7+V6'
MK7@VX\N*PU+%4U[T8OF5.M%35K*:DDY*TG6'Q$,33=2FI1BJM>BU))/FP]>I
M0F[1E)<KG2;B[W<;-I.Z49CB4ABJY'0E02.=PP<9&",CT.3UJ0<\CH:_'K]M
M'X^^.?AQ^U#HOAWXJ_M*?&G]B[]D.+X+>&=1T/X\?"GX"_#OQKX*\3_'GQ;\
M4_$7AC7?"WQU^/?Q9^$'Q^^'GP/\.^"/"NC^`KCP5INO^#_AWI_C+4OB/XIU
M#6/B=<#POH_A=OO[]EC4DU?X)>%]2M_VE=+_`&O=.O\`5?'=WH/[06CVOPPM
M[3QOX8F^('B>3PM8S3?!>QTKX7:MJG@7PX^E?#W6_$7@W1M`TWQ/K'A2^\12
M^'=`O]4N](LNS$Y76PN!PN.G.$J>*5-T_9T\7*/OPE-P>(>%C@G6HJ*CB*-/
M%U*M&<O9R@ITZ\:7/A\?3Q&*KX6%*<7AW)3E*="+O"48O]PJKQ,82YG*G5J4
M84ZL%SPE*,Z;G]#T445YAWA1110`51U/2]-UO3[W2-8L+35-*U*VGLM1TW4+
M>*[L-0LKJ)H;FSOK.=7M[NTN87>&XMKB.2">)VCEC=&(-ZB@#X^\9_L`_L:^
M.OL!U?\`9Z^'VDMIB3QVK>!+*]^&.Y)PH9+X?#:^\)C5$C"*+=-4%XMJ-PMA
M"'<-_+-_P5J_:@^.W_!+G]N'P-\`OV%O'LOP,^$WQ#_9H^'/Q1\9^%4\/>%/
MB0VM^.KGXJ_'#PC-K9U[XO:%\0/$VGAM`\+Z)8?V9IFLV>C@V9NQ8"]N;NYN
M/[6J_@J_X.:03_P5#^"6`2?^&*?ACP.3_P`EY_:1/\@3^%?HGA?@L'C^+*&'
MQV$PV-H?4<PJ.ABZ%+$47.GAVX3=*M"<'*$O>A+EO&2333/EN,,1B,-E$:N%
MKUL/4^OX"#J4*LZ4^2>(BIQYX2C+EDM)1O:2T::/1OAK^W+^V#\>+O0V^(O[
M1_Q;D^R7$-R@\$>+]2^$R3.\T<C1WL?PFD\$1ZA:LR(&LK]+FS>-%C:`IE3^
M\_P1EE^)FB:9K_Q'EE^(&O>$+&[U'PKKGC:1_%6L^&]1N;-+.XU#0M4UUK^^
MTJ^GM9'MYKNQG@N)87:-Y&5B#_/M^P[^R+^U'\1K'3O$/@WX"?$O4M`G\,6_
MB[1O$>J:#_PA_A/Q1HSNBVLGA/QEXYN?#/A#Q)<7SE/L=KI.NW,TL,GVXJNG
MQSW<7]1'[/O[*/Q7\.>%[:T\9ZOH'@J#4]*TPWMKI$G_``D_C*TM]4\/:I'K
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MCQ`D&IZ[K-I!KFOSA]2U"QTO4O$_B*;0=)DG_L;PS!K%[IOAK3])TITL4])K
M\\S+B'$XS`TLJH.5#+Z;A.I'15,54A;D=:VU*FUS0I7:Y[5)MSC3]GZ=/#QC
M4=67O3UY?[B>]GU<M+M[;+NRODGXU?LQ3_%S]I;]C;]H./QFF@Q?LF^)?C5X
MCD\*-X?_`+3;QX?B]\&_$/PD6R76_P"W-._X1G_A'QX@;Q`;G^R/$']J?8QI
M/D:=]I_M.W^MJ*\.A7JX:HZM&7)-T<3AV^6,KTL7AZN%Q$+2C)+GH5JD.96E
M&_-%J236M6E3K14*D>:*J4JJ6JM4H585J4M.L*M.$ET=K---IH!@5X=^T[\'
MI?VAOV;OC_\``*'71X6E^-_P5^*/PBC\3MI@UI?#;_$GP3K?@T:^VC'4M'_M
M==&_MDZB=+_M?2SJ`MC:#4+(S"YC]RHJ:56=&K3K4GRU*52%6G*RERSA)2@[
M23B[22=I)I[--#G3A4ISI35X5(2ISCM>$DXR6EFKIM:'B?[.GPC?X#_L\?`[
MX%R:W_PE$OP:^#GPW^$__"2G3AHH\1GX>>"]&\(#7O[&74=8&C_VR-(&H'2O
M[6U4:=]I^Q_VC?>3]JE;^S-\'W_9Z_9Q^`'P#?7SXK?X(?!3X5_"!O%)TI="
M_P"$E/PU\"Z#X+.O_P!AKJFMKHW]L_V+_:/]E#6=6&G?:?LG]IW_`)/VJ7VZ
MBM)XO$5(UX3J<T<3B(XJNN2"YZ\?;6G[L5R6^L5?<ARP][X?=C;..&HQJ4ZL
M86G2HSP]-\TK1I5)4I2C:]GK1IVDTY)1LG9N_P`#_M9_L)>&_P!L_P"*WP%U
M?XT^--<NO@+\";KQ!X_L?@EX3G\0>!]2\7?'F>*#1?`?Q-\0?%CPGXMT?QAI
MNG_"WPQ?^,1X0\-^#8?#.I'Q9XG_`.$@U;Q=J&FZ?%X:E\K\6?\`!*?X(Z7\
M0_@9\<OV?_$?Q+^$OQ[^`/Q-T[QCX/\`B!XO^*?Q>_:)TR]\$:U:77A;XQ_"
M;5_!OQW^)OB_2[/PS\6_AYJFJ^'-1UWP?=>%/&?AO7(O#/BW2-=F/AR30=9_
M4RBNRCG6:X>E0H4<=7IX>A3JT8X:,O\`99TJ\ZLZ].OAFG0Q"KNM4C6]O3J2
MJTFJ,W*E"$(\]7+,!6J5*M7"TIUJM6E6=:4;UH5:"IJC.E5?[RBZ7LH2I^RE
M!0J)U8I5)3E)B[M@W`EN"1D'D>_3^7X5\2ZW^Q)\/?B/X1_;6^'7QBCM?'OP
M]_;0^(EAXY\0^';G1;.TN/!<>G_L^_`/X(Z?#HNISW^LI<^*/#VL_`G3?BCX
M/\<0:?HNH^%/%=]HL^DV*:GX2M=>U'[=HKCPV+Q&$<I8:M.C.:IIS@TJB]C7
MHXFE*%2W/3G"O0HU8U*<HS4H+WK-I]%;#4,1R*M3510=3EC+6-JM&I0J1E%^
M[4C.E5G!QFI1=[VYDFO&/V??!GQ3^'7P@\">`_C-\3K+XT_$/PEH5OH&O?%B
MT\&GX?S>/WTV6XMK'Q)K/A/_`(2OQK#I_B>_TJ/3G\5W=EK[:7KGB7^U=>TK
M1O"VG:E;>%M&P/C9\#Y?C!XU_9G\5?\`"0G08OV=_CO<?&MK+^R4U4>,1=_`
MGXY?!)_#!N?[7TQ_#_E#XRCQ/_;0MM;WCPZVBC25;5AJNF_0U%"Q5=8BIBH2
MC3K577YG2HT:5-+$QG"M&%"G3C0IPE3J3A&G3IQIPA+EIQC:-B6'I2HTZ$E*
M5.G['DYJE24[X>I"I2E*K*3J3DI4X\TIRDZBYE4YN9W_`#>^&W_!.7P%\/OV
MS?'G[6#^+=;\1:-?7'C[Q;\'/@MK&C>&KKPA\!_B_P#'>V\'V7[3/Q8\">(;
MBTG\70:[\:K?X>^%Y;G38-0TS3?#5[XB^-<D/]KVWQ@U*UT;VK]AO]F";]C?
M]FGP7^SS+XT'Q!/@_P`2?%O7QXL'AT>%/[1_X6C\9/'_`,61;?V$->\3?9!H
MB^.!H'G'6;@ZE_9?]J&#3_MO]G6GUO173B<VS#&4?88K$SK4O]C7+.-/;`4L
M51PVL8)WBL;BJE62?/B<16GB<3*K7?M#*AE^$PTU5HT5"HGBK3YIM_[9/#5,
M0K2DXVD\)AXP5K4J=*%&ER4HQ@OB?]L/]D$?ME2?!OP'X^\=7NE_L[>#_B!/
M\1?C%\*O#_\`PG'AOQ%\;-0\.Z!>CX4:#+\3_`WQ0\$ZEX/\*^"/B'=6'Q.U
M72?^$:\4W7B7Q1X/\"3Z=JWA&30)[G4_`OBY_P`$G?@KKOA[1=8^`OC7XO\`
MP0^/7P\\:>#_`(E?!GXQZ_\`'+]I#X]6'P[\=>$=<M+QM0N/A7\4_CQ=^"O%
MVE^*/"LGBCX=>*M%U<00ZKX*\:^)M*-S$M^[5^JM%7ALZS7!0PU+"XZOAZ.%
M;E"A2ER4*DI5'4J/%4$O98QUK^RK/%PK>UP\:>%J<V&ITZ4<ZV5Y?B)UJE?"
MTJU6NHJ56I%2JP4(*$/857^\P_L[<]/V,H<E:4ZT.6K.4W%$)1$HE(:4`AV7
M`#$9&X`<+NX('.W."21D_`GC?]EGXW^$?C]\1?VB_P!DWXW:!\/M9^-6F^&V
M^.7P;^-?@KQ-\6_@=\0O&'@K2?#?A'PI\3O"-GH/Q.^'OBGX*?%9?ASX8TKX
M<>*_$GAF\\2>!_&_A?1?!EQXG^%VI^*?!NG>(Y?T`HKCPV*K8251T7"U:DZ%
M:G4I4JU&M1<X5/9U*5:$Z<DJE.G4@^53I5(0JTI0J0A./37PU+$J"J*5Z<U4
MI3IU)TJE*HDXJ<*E.491?+)Q:ORRBY0FI0DXOY=^$'@[]K*'Q[JWC/X_?&KX
M;:MX7?PV^A^&?@Q\&OA+-X2\*Z7JD^L17USXP\7_`!!\=>,?'_C[QOXD@TZR
MM])T&'PVGPG\(:99:IXB&N^$/%^JOX=UWP]]'ZU8G5-'U73`YC.H:=>V(D"A
MS&;NVD@WA&DB5RGF;@AEC#$8,B`[AIT5-6O.K455JE3E%1451H4:$(\GPOV=
M*G"#DOM3E&4YO6I*;U+ITHTH<D74DFVW*K6JUIMRW]^K.<HIO50BXPA>T(QC
M9+\S?@A^S3^WO\`?@G\(?@5X,_:N_9+U+PI\&/ACX`^%'AC4/$G["?Q<O/$-
M_P"'OAYX6TGPAI%[KM[IO_!1+2--NM9N=-TBWN-2N;#1M,LIKUYI+33+.!H[
M6+],5&`!]?YTM%:8O&U\=5E6Q'L75G.I4G.EAL-AG.=67-.4_JU&DIRE+6\D
M[-OEM=WRPN$HX.FJ5!UO9QA3IQC5Q%>NH0I1Y(1A[:I4Y4HV7NVNDKWLCX-^
M*/[-GQWTS]IG4/VI?V9?BUX"\*ZWXZ^%O@SX2_&KX3?%KX;3^+O`_P`1=)^&
M?BGQ5XA^&?B_PYXP\*>)_!_C?X<^/O"4'Q*^)NBW]Y=?\+!\'^+-#UO0K*\\
M%Z9JGAFRU^3HOV9_V=?BU\//B?\`'+]H#]H#XP:'\5/C#\=-(^$W@^;2_`/@
M&?X<?"?X7_#7X,V7C"Y\'^!_`N@ZUXN^(/C'4[RX\9?%#XI>,?%WC#Q/XTNF
M\1:CXHLX-'\+^#=-T:/3KG[0HK:>9XN="6'E*ERSP]'"U*D<-AXXBIAJ$Z52
MC0J8B-)5IPIRH4+.4W-PHTJ4I.E3C!1'`8>-95TJG-&K4KQINM4=&%:JIJI5
MA1<O9QG-5*G,U'XJE2:2G.4F5\V>!/@%-X,_:A_:$_:+;Q.-0B^.?PV_9]^'
MR>$_[%%H?#)^!.I?&S4/[6.N_P!L71UG_A*?^%R-$+#^Q=)&B#PV)/MNK'6/
M*TKZ3HKEIUZM&&(ITY<L,51C0KJR?/2C7H8E1U3<;5L/1GS1M+W>6_+*2?1.
ME3J2I3G'FE0J.K2UDE&;I5*+E9-*7[NK-)232;YDN9)HKY8^&7[-;_#S]JS]
MJ7]IIO&0U8?M)^#?V</"*^"O^$>^PGP;_P`,_P"F_%&Q;4#XC_MV]_X2'_A+
M#\2O,%I_86A_V%_8FW[3K`U(-8?4]%%*O5HPQ%.G+EABJ*P]=<L7ST8XBABE
M"\HMPM7PU"?-!QE[G(Y<DIQD3I0J2HSFFY4*CJT]6K3=*K0;:37,O9UJD>65
MXWDI6YHQ:X_XA>`?"/Q5\`^-_A?\0-&A\1^`_B/X0\2^`O&OAZXN+VTM]>\(
M^,-%O?#WB31I[K3KFSU"WAU31M1O;&6>QN[6\ACG:2VN()E21?@CX9?L_?MW
M_L\^`?#OP3^%'[1_P+^)WPN\"^&]/\#_``N\2_M"_`KQ7=?&+P5X1T`VVF^%
M;+QYKWPJ^,?@+P9\;I_#OA:&#0K:^LO!/P2UO6%TJRO_`!/KFM:Y>:KKMY^D
M]%;8?'8C#4IT(>RJ4*DXU)4<1AZ&(IJK!652"K4YNE-Q]R<J3A[6"4*O/&,%
M'*MA*5:I&J_:0JPBX*I1JSI2<)-2<)\DDJD;Q3BIJ7(VY0Y9-M^8_!_PS\2?
M"/@+2]'^+OQ/C^,'Q"^V:UJ7B#QO:>"-%^'&D7$NLZS?ZK:Z)X<\%Z+>:NNA
M>%_"ME>6WAGPW;ZSXD\7^*I-%TFRN?%GC/Q9XBFU+7K_`.6?VM?V%O#/[9_Q
M,^`^H?&GQ?KE_P#`;X':CX@\?P?`[PR^L^#+KQC\<KFTCT/P#\4=>^+'ACQ7
MI'C71K?X2>';_P`8OX/\.>"(O#.IS^+?%,7B/5O&%WI^AP>&KK[THI4<=BL-
MB7C,-5^KXE^VM5H0IT'3=>$Z=25"-*$(8:2C4E[*6'C2EAY6EAW2E"#B5<)0
MKT(X:M!UJ$71;A5G.IS^PG"I3564Y2E67/"+FJKFJMFJJFI23_+3Q7_P2G^"
M.F>/_@G\;/@!XD^)/PD^//P&^)&G>,/!?Q#\8_$_XO?M':9/X.U6UN/#/Q?^
M%.J^#/CM\4/%5C8^&/B_\.M3UCPKJVN>!]2\%^-=`UA/"WBK3?$5Q'X:E\/Z
MS^I0R1R.?\#UX_SVI:*,5CL9CHT5C,36Q7U>-2G1G7E[2K"G4DINE[:5ZLJ4
M9\TZ=.<Y0I3JUI4E!U:G,8?!X;"NJ\-1A05:495(4DH4Y3C'D53V4;4XU'!1
MA*<8J4XPIJ;ER1M\"M^SO^UCX(^+G[17CWX%_M$?L_\`A3PC^T'\4_#OQ;O_
M``E\5OV3_B%\5O$/AKQ#HOP'^"_P)NK*S\:>$OVR_@IIVHZ/J&F_!;2?$%O;
MS^!K:]T^^UG4;*34-1@@MYS]M>%+?Q1:>&=`M?&^KZ'K_C&WTC3X?%&N>&?#
MM]X1\.:OKR6T:ZKJ.@^%=3\3^-=2\.:1=WHFGT[0[_QCXKO=+M'BLKKQ'K4\
M+ZC<]!11B<=B,6J:KNC+V5.E2C*&%PE&HX4*,*%)5*U&A3JU>2C3A"]6<W*W
M//FG>04,+2P\JCI>TBJDZM24)5JLZ:G6JRK5)0ISG*%/FJ3E*U-1BN9I)+0^
M2OB]X1_;-D^(MQXF^`WQ?^!T'P[U/P1I7AVY^$OQF^$'B76_["\96%]XWN[W
MXC>'_B5X%^)7A36YX]>M=<\(:-KG@#Q!X8U;37L_!4%YX=\2^%=0UK6Y+WG/
MV&?V/T_8Z\"?%S1+[QM!X_\`&7QV_:.^+O[3GQ(UO1O",?P]\$6OCKXN7^ER
MZAH7PX\`'Q%XTO\`P=X&T32]#T;3],TC6O'7C76IKZ'4]7OO$4YU.*QL/MBB
MJ>/Q+PKP2=&G0G['VJHX;#T:E?V%W1]O5ITHU*O(Y.3<I-U)VG5YYQC))8.@
ML2L4_:3K1]I[-U*U6I"C[:WM52ISFX04[+11]Q*U/DBY)E%%%<1U!1110`44
M44`%?E;XT_8)\!_&K_@JU!^V+\8/`:>+-#^!G[(GP-\%?`]?$%G;:AX,;XN7
MGQJ_:7\3>*_%#:=<!X=0\6_"[0'\$W/AH:A#=:?HNH?$&U\5V-M%XLT#PQK&
MB_JE1BNS!X[$X!XB>%JSHU,1A:V$G4IR<9QHU^55HQDMO:TU*C/O3J36E[G/
MB,-1Q2I1KPC4C2K4\1&,E>/M:3;IR:Z\DFIQOIS13::T$`"C```]!P.>:6BB
MN/\`X8Z`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
